SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): June 6, 2003

 

 

ALEXION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

(State or other jurisdiction of incorporation)

 

 

0-27756		13-3648318
(Commission File Number)		(IRS Employer Identification No.)

 

 

352 Knotter Drive

Cheshire, CT 06410

(Address of Principal Executive Offices)

 

 

Registrant’s telephone number, including area code (203) 272-2596

 

 

None

(Former Name or Former Address, if Changed Since Last Report.)

---

ITEM 7.    FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

 

(a)

Financial Statements.

 

None.

 

(b)

Pro Forma Financial Information.

 

None.

 

(c)

Exhibits

 

99.1.    Press Release of Alexion Pharmaceuticals, Inc. (the “Company”) issued on June 6, 2003 relating to its third quarter earnings.

 

ITEM 9.    REGULATION FD DISCLOSURE.

 

The following information is furnished under “Item 12. Results of Operations and Financial Condition,” in accordance with SEC Release No. 34-47583.

 

On June 6, 2003, the Company announced its results of operations for the third fiscal quarter and the nine months ended April 30, 2003. A copy of the press release issued by the Company relating thereto is furnished herewith as Exhibit 99.1.

 

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

						Alexion Pharmaceuticals, Inc.
						By:		/s/    LEONARD BELL, M.D.
								Leonard Bell, M.D. Chief Executive Officer,     Secretary and Treasurer

Dated: June 10, 2003